Resources

Truveris experts explore the expanding GLP-1 market, biosimilars, the 2026 drug pipeline, and emerging policy changes that could reshape PBM dynamics.

Stay informed about the new TrumpRx GLP-1 pharmacy pricing updates before they begin influencing your pharmacy strategy in 2026.

TrumpRx signals a push towards consumer-facing drug pricing with more drug pricing announcements increasing in momentum.

Understand how effective utilization management programs balance clinical appropriateness, cost control, and member experience.

Most-Favored Nation (MFN) pricing refers to matching the lowest available price for a drug in peer nations. Emerging MFN arrangements with pharma manufacturers could drive broader adoption.

The Trump administration’s pharmaceutical tariffs policy is intended to encourage U.S.-based manufacturing, reduce reliance on foreign supply chains, and lower drug costs.

Truveris experts discuss 100% pharma tariffs, Most Favored Nation pricing, and TrumpRx, with key considerations for plans.

This blog reviews the basics of PBM guarantee terms, where they can lose value, and shares steps employers can take to keep guarantees working in their favor.

Access our latest eBook about reducing total pharmacy costs while centering around plan transparency and aligned incentives.

Lowest net cost is a structured way to contract, design, and manage pharmacy benefits so that results match financial goals and member needs.

Truveris experts break down how pharmacy guarantees work, hidden factors that can water them down, and best practices for reviewing guarantees.

Learn about the role played by your Pharmacy Benefits Manager (PBM) in reducing specialty drug costs and administering your pharmacy benefit.

Truveris has created a series of resources (eBook, case study, and more) to support GLP-1 cost management strategies.

Market checks typically take place during a contract term and compare the plan’s financials to pricing in the market.

Pharmacy benefits procurement helps plan sponsors secure the right PBM and negotiate favorable contract terms.

For plans navigating GLP-1 coverage, it’s important to understand their utilization as you build pharmacy spend strategies.

Truveris experts break down the latest market trends, cost considerations, and real-world strategies for managing GLP-1 costs.

Explore 4 key milestones in the PBM contract lifecycle that ensure maximum savings.

Learn more about three critical areas impacting pharmacy benefits strategies in 2025.

Truveris experts explore the top 5 trends shaping pharmacy benefits in 2025.

Learn more about the importance of PBM oversight for pharmacy plans.

Access our latest eBook that takes a deep dive into pharmacy coalitions.

Truveris experts explore explore the key elements of comprehensive pharmacy reporting and effective oversight.

Explore 3 strategies to enhance PBM accountability and drive pharmacy transparency.

Truveris experts explore recent PBM news and strategies to enhance PBM transparency and accountability.

Access our latest eBook on how employers can best navigate the rising costs of GLP-1s in pharmacy benefits.

Understanding the ins and outs of drug formularies is essential to making an informed decision on which PBM to select for your members.

Learn more about the strategies to manage rising specialty drug costs in pharmacy contracts.

Access our latest eBook on how employers can best navigate fiduciary duty in pharmacy benefits.

Truveris pharmacy contract experts explore strategies for plan sponsors to effectively manage rising specialty costs.

Take a deep dive into some of the key federal and state PBM transparency initiatives.

Stay up to date on the GLP-1 landscape with our latest news roundup blog.

Learn more about federal and state initiatives focused on PBM transparency and important considerations for brokers and employers.

Discover how carve-in plans can strategically control pharmacy benefits, negotiate better contracts, and achieve optimal savings.

Explore the top 5 pharmacy benefits trends that brokers and employers need to pay attention to in 2024.

Learn more about the differences between self-funded and fully insured health plans and their impact to pharmacy programs.

Truveris experts take a deep dive into the biosimilars landscape and explore effective approaches for plan sponsors.

Discover how the removal of the Average Manufacturer Price (AMP) cap within the American Rescue Plan Act is reshaping the pharmacy contracts and impacting plan sponsors.

Learn what brokers and employers need to know about the impact of GLP-1 coverage and spend on pharmacy benefits spend.

Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?

Truveris experts discuss GLP1s (such as Ozempic), the AMP cap in the American Rescue Plan Act, and their impact to pharmacy programs.

Explore the strategies for achieving transparency in pharmacy benefit contracts, a crucial need for employers grappling with rising costs.

Explore how pharmacy coalitions work and the key considerations for brokers and employers to keep in mind when evaluating them.

Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?

The importance of transparency in pharmacy benefits and PBM contracts is becoming more prevalent as list prices of specialty drugs increase and plans become more restrictive.

Alternative funding programs seek to reduce pharmacy spend on specialty drugs by finding alternative sources outside of your pharmacy benefits plan.

Watch as Truveris experts explore the key contract elements and metrics that drive a transparent pharmacy strategy and pricing performance.

In today’s pharmacy environment, many cost containment approaches are losing their effectiveness. These strategies can help employers maximize their pharmacy benefits and reduce costs.

Watch Truveris experts discuss market trends and key considerations for how to develop an effective pharmacy benefits contract strategy.

By understanding your contract, communicating with your PBM, and working with a partner to craft your pharmacy strategy, you’ll be well prepared for the rise of biosimilar drugs.

Biosimilars disrupted the drug chain in 2023. What do brokers and plan sponsors need to know for this year and beyond?

How can you build more transparency in your pharmacy contract? We lay out five critical strategies to ensure you have control and oversight over your program.

In this Truveris webinar, we join Mployer Advisor to tackle pharmacy benefits 101. What should payers know about PBMs as they plan for 2023?

How can you inject more transparency into your pharmacy plan? Watch the recording of our webinar.

Read what issues the HR leaders at Equinox, Kyndryl, and Phreesia are citing as the biggest benefit challenges this year.

If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?

Watch Truveris’ exclusive Human Resources round table, originally recorded on June 8th, 2022.

As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?

Read Sally Welborn’s POV piece on the misaligned incentives at play in the pharmacy benefits ecosystem – and what it means for plan sponsors.

How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.

Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.

While a pharmacy benefits contract is a powerful lever for managing spend, it is also very complicated, with variables impacted by market and industry dynamics.

Watch the recording of our webinar and Q&A, led by Clinical Director, Adrienne Trudell (PharmD, BCGP, CPBS), to learn strategies to proactively manage your PBM contract.

340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?

What is the future of the PBM landscape? Listen to Truveris CEO, Nanette Oddo, opine on the shifts she’s seeing in the pharmacy ecosystem.

Several states have passed copay accumulator laws that prohibit the use of copay accumulator adjustment programs. How does this affect your organization?

Generic versions of brand name medications are not all the same. Understand how generics impact MAC pricing to choose the most-cost effective PBM.

Watch Truveris’ on-demand webinar outlining how Payers can best anticipate and manage new gene therapies.

Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.  

Watch Truveris’ webinar to learn more about how you can better manage a self-funded specialty pharmacy program.

Pharmacy Benefits Managers, also referred to as PBMs, are the intermediaries between every stakeholder in the pharmacy ecosystem.

Why type of plan sponsor could benefit from carving out their pharmacy plan?

Get up to speed on all the industry-speak and confusing jargon that surrounds the work of PBMs.

The price of drugs on your pharmacy benefits plan can vary dramatically, depending on its type: single source brand drugs, single source generic drugs, or others in the MONY system.

In October of 2017, Anthem Inc. announced its launching of IngenioRx, an in-house pharmacy benefits manager (PBM).